Pfizer To Conduct More Tests On Remoxy
Pfizer Inc. (NYSE: PFE) will conduct additional tests on Pain Therapeutics Inc.'s (Nasdaq: PTIE) pain treatment Remoxy before deciding whether or not to continue developing the medication. Durect Corp.'s (NYSE: DRRX) Oradur technology was used to formulate Remoxy. Shares of Pfizer lost 32 cents to close at $24.55 while Pain Therapeutics stock plummeted $1.71 to close at $2.96. Durect stock plunged 46 cents to close at $0.91.
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here